AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 11/07/23

2023-11-07 06:04:37 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal Pharmaceuticals raises its FY outlook Amneal to reorganize and simplify corporate structure Seeking Alpha’s Quant Rating on Amn...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Amneal Pharmaceuticals Inc. Class A (AMRX) is expected to report $0.1 for Q3 2023

2023-11-06 11:32:09 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is $0.13 (-7.1% Y/Y) and the consensus Revenue Estimate is $604.53M (+10.8% Y/Y). Over the...

2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...

2023-10-23 16:23:28 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal to reorganize and simplify corporate structure Amneal gets approval for generic injectable on FDA's shortage list For further details ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...

2023-10-17 16:34:51 ET Amneal Pharmaceuticals ( NYSE: AMRX ) said that it plans to reorganize and simplify its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure. The biotech company said it intends to convert to a more traditional c...

- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...